-
DE
Dickkopf 1 (DKK1) is a signaling protein that inhibits the Wnt pathway and plays a key role in bone formation, embryonic development, and tumor biology.
Dickkopf 1 (DKK1) is a signaling protein that inhibits the Wnt pathway and plays a key role in bone formation, embryonic development, and tumor biology.
Dickkopf 1 (abbreviated DKK1) is a secreted glycoprotein belonging to the Dickkopf protein family (DKK1–4). It acts as a natural inhibitor of the canonical Wnt signaling pathway, a central regulatory circuit governing cell growth, differentiation, and tissue regeneration. The name derives from the German word for “stubborn head” and was coined in the 1990s when the protein was first identified as a head-induction factor in frog embryos.
DKK1 binds to the co-receptors LRP5 and LRP6 (Low-Density Lipoprotein Receptor-related Proteins), which together with Frizzled receptors form the Wnt receptor complex. By binding to these co-receptors, DKK1 prevents activation of the intracellular β-catenin pathway. As a result, β-catenin cannot translocate to the cell nucleus and cannot activate the transcription of Wnt target genes.
DKK1 plays a critical role in bone remodeling. It inhibits the differentiation of osteoblasts (bone-forming cells), thereby indirectly promoting bone resorption. Elevated DKK1 levels are associated with the following conditions:
During embryonic development, DKK1 is essential for the formation of the anterior head region. Experiments in zebrafish and mice demonstrated that the absence of DKK1 leads to severe head malformations. DKK1 acts as a head organizer by suppressing Wnt signaling in the anterior part of the developing embryo.
DKK1 is dysregulated in various tumor types:
DKK1 is therefore being investigated as a potential biomarker and therapeutic target in oncology. Monoclonal antibodies targeting DKK1 (e.g., BHQ880) are currently being evaluated in clinical trials.
Serum levels of DKK1 can be measured using ELISA (Enzyme-Linked Immunosorbent Assay). Elevated levels are found in:
Targeted inhibition of DKK1 is considered a promising therapeutic strategy to prevent bone loss in oncological diseases. BHQ880 is a humanized monoclonal antibody against DKK1 that has been studied in clinical trials for multiple myeloma. In addition, DKK1 inhibitors are being explored in the context of osteoporosis treatment and fracture healing.
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, lactic acid bacteria, and Lactoferrin CLN®
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.